SCIENCESCIENTIFIC AMERICAN
Aviv Regev
Aviv Regev, a biotech executive, discusses the current inflection point in biomedical science and the positive role of frustration.
Related Signal
Adjacent reporting
- Sally Kornbluth
- STAT+: Pharmalittle: We’re reading about U.S. biotech’s China problem, a Regeneron flop, and much more
- Biotech exec Jeremy Levin on the industry’s strategic turning point
- STAT+: Pharmalittle: We’re reading about biotech investors’ mood, a former FDA head’s confidence, and more
- Chris Boshoff
- STAT+: Even at a meeting in Rome, FDA shifts are top of mind for gene therapy field